Evidence map›Paper›PMID 37738628›Full record

ReviewThe journals of gerontology. Series A, Biological sciences and medical sciences2023

The Triple Alliance: Microbiome, Mitochondria, and Metabolites in the Context of Age-Related Cognitive Decline and Alzheimer's Disease.

Santosh K Prajapati, Ria Shah, Nicholas Alford, Sidharth P Mishra, Shalini Jain, Barbara Hansen, Paul Sanberg, Anthony J A Molina, Hariom Yadav

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journals of gerontology. Series A, Biological sciences and medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Gut microbiome and bone health: update on mechanisms, clinical correlations, and possible treatment strategies.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Age-Related Cognitive Decline and Dementia: Interface of Microbiome-Immune-Neuronal Interactions.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Santosh K PrajapatiUSF Center for Microbiome Research, Microbiomes Institute, University of South Florida, Tampa, Florida, USA.
Ria ShahUSF Center for Microbiome Research, Microbiomes Institute, University of South Florida, Tampa, Florida, USA.
Nicholas AlfordUSF Center for Microbiome Research, Microbiomes Institute, University of South Florida, Tampa, Florida, USA.
Sidharth P MishraUSF Center for Microbiome Research, Microbiomes Institute, University of South Florida, Tampa, Florida, USA.
Shalini JainUSF Center for Microbiome Research, Microbiomes Institute, University of South Florida, Tampa, Florida, USA.
Barbara HansenDepartment of Internal Medicine Department, University of South Florida, Tampa, Florida, USA.
Paul SanbergCenter of Excellence for Aging and Brain Repair, University of South Florida, Tampa, Flordia, USA.
Anthony J A MolinaDivision of Geriatrics and Gerontology, School of Medicine, University of California San Diego, La Jolla, California, USA.
Hariom YadavUSF Center for Microbiome Research, Microbiomes Institute, University of South Florida, Tampa, Florida, USA.ORCID 0000-0003-4504-1597
University of South Florida · USUniversity of California San Diego · US

Funding

Blood Base Bioenergetic Profiling: A Novel Approach for Identifying Alzheimer's Disease Risk and PathologyR01AG054523 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MOLINA, ANTHONY J, NICKLAS, BARBARA J · 2017 to 2021
$3.8M
Exosome Mediated Alterations in Cellular Metabolism in the Pathogenesis and Progression of Alzheimer's DiseaseR01AG061805 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MOLINA, ANTHONY J · 2018 to 2022
$3.5M
Repurposing of Metormin for Older Patients with HFpEFU01AG076928 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KITZMAN, DALANE W, YADAV, HARIOM · 2022 to 2024
$2.3M
Gut microbiota-based biomarkers of Alzheimer's disease and its modulation by a ketogenic dietR56AG064075 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI YADAV, HARIOM · 2020 to 2021
$1.2M
Microbial therapy improves gut permeability to reduce cognitive decline and Alzheimer’s diseaseRF1AG071762 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI YADAV, HARIOM · 2021 to 2021
$1.1M
The role of gut microbiota in the efficacy of ketogenic diet to ameliorate Alzheimer's diseaseR21AG072379 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI YADAV, HARIOM · 2021 to 2021
$429k
Identification of bacterial strains for development of an oral probiotic aimed at increasing nitric oxide bioavailabilityR21DE032197 · NIDCR · WAKE FOREST UNIVERSITY · PI KIM-SHAPIRO, DANIEL B, YADAV, HARIOM · 2023 to 2024
$422k
Metformin and Alzheimer's disease: Underlying Mechanisms that Ameliorate ProgressionR56AG069676 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI YADAV, HARIOM · 2020 to 2020
$388k
NIA NIH HHS R01 AG054523NIA NIH HHS R01 AG061805NIA NIH HHS R21 AG072379NIA NIH HHS R56 AG064075NIA NIH HHS R56 AG069676NIA NIH HHS RF1 AG071762NIA NIH HHS U01 AG076928NIDCR NIH HHS R21 DE032197NIH HHS
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive, age-related neurodegenerative disorder that affects a large proportion of the older population. It currently lacks effective treatments, placing a heavy burden on patients, families, health care systems, and society. This is mainly due to our limited comprehension of the pathophysiology of AD progression, as well as the lack of effective drug targets and intervention timing to address the underlying pathology. AD is a multifactorial condition, and emerging evidence suggests that abnormalities in the gut microbiota play a significant role as environmental and multifaceted contributors to AD, although the exact mechanisms are yet to be fully explored. Changes in the composition of microbiota influence host neuronal health through their metabolites. These metabolites regulate intestinal epithelia, blood-brain barrier permeability, and neuroinflammation by affecting mitochondrial function. The decline in the proportion of beneficial microbes and their essential metabolites during aging and AD is directly linked to poor mitochondrial function, although the specific mechanisms remain unclear. In this review, we discuss recent developments in understanding the impact of the microbiome and its metabolites on various cell types, their influence on the integrity of the gut and blood-brain barriers, systemic and brain inflammation, and cell-specific effects in AD pathology. This information is expected to pave the way for a new understanding of the interactions between microbiota and mitochondria in AD, providing a foundation for the development of novel treatments for AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionGastrointestinal MicrobiomeMicrobiotaBrainHumansMitochondriaNerve DegenerationAlzheimer’s diseaseMetabolitesMicrobiomeMitochondria

Identifiers

PMID37738628
PMCPMC10692438
OpenAlexW4386949099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.